The Latest Triple-Positive MBC Research
MBC tumors are commonly assessed for three markers: estrogen receptor (ER), progesterone receptor (PR), and HER2. The presence or absence of these markers—and how...
Read More PAST ARTICLES
2024
- Combining Radiation and Immunotherapy Treatment for MBC
- Can I Know if My MBC Treatment is Likely to Work?
- The Latest in Treatments for MBC With Brain Metastases
- What You Need to Know About De Novo MBC Research
- Update on Oral SERDs and New Types of Hormone Therapies
- Turning “Cold” Tumors Into “Hot” Tumors: Researching How to Make Immunotherapy Work in More People With MBC
- Targeting the Androgen Receptor in MBC
- Dato-DXd Antibody-Drug Conjugate for Triple-Negative and Hormone Receptor-Positive MBC
- Leptomeningeal Disease: How is it Different from Brain Metastasis and How is it Treated?
- Discovering New Ways to Overcome Treatment Resistance in Triple-Negative MBC
2023
2021
- What do FGFR Genetic Mutations Mean for You and Your MBC?
- Metronomic Chemotherapy: Looking at A New Way to Receive Treatment
- Lobular Metastatic Breast Cancer
- Inflammatory MBC Treatments
- Atezolizumab Immunotherapy Is Withdrawn From FDA-Approval Process
- Cell-Based Therapies: A Type of Immunotherapy for MBC
- Immunotherapy Resistance
- Update on Oral SERDs for Estrogen Receptor-Positive MBC
- Lymphodepletion in Cancer Immunotherapy
- Local Therapies for Liver Mets
- Y-90 Internal Radiation Therapy for Liver Mets
SEARCH OUR SITE
for past articles or specific information.